Only High CBD in a state-sponsored clinical trial
In 2014, the Alabama passed SB 174, a restrictive cannabidiol (CBD) law. Officially titled “Carly’s Law,” it offers a defense for the possession and use of CBD; however, the program is extremely limited and may not be able to provide CBD-rich medicine to patients in Alabama.
At the time, the law only allows for CBD access after a medical practitioner at the University of Alabama-Birmingham’s Department of Neurology has made a diagnosis for a “debilitating epileptic condition.” Then, the doctor may “prescribe” CBD-rich treatment, if the CBD extracts are less than 3% THC and “essentially free of plant material.”
Patient Registry or ID Cards Program?
Existing state law allows qualified patients to use CBD if they are part of state-sponsored clinical trial. It also legally protects qualified patients who possess the substance outside of a clinical trial environment, such as in their home, etc.
In 2016, HB 61 (also known as Leni’s Law) was passed, which expanded the definition of qualifying conditions to cover several more and removed the requirement that patients must be enrolled in the UAB study program. Under HB 61, patients can be defended by Leni’s Law, if they are diagnosed with a debilitating condition, regardless of age. But the parents of minor-aged patients may be ineligible for legal protections. However, physicians cannot write prescriptions for medical cannabis.
No Home Cultivation
Alabama allowed for high CBD oil extracts in clinical trials only in 2014.
Important Cannabis Laws
SB174, “Carly’s Law” (2014) : relates an affirmative defense for the possession and use of CBD under limited circumstances.
HB61 (2016) : extends low-THC extract affirmative defense to patients with more qualifying conditions as well as parent caregivers.